<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02621476</url>
  </required_header>
  <id_info>
    <org_study_id>CN-14-1947</org_study_id>
    <secondary_id>R18DK104249</secondary_id>
    <nct_id>NCT02621476</nct_id>
  </id_info>
  <brief_title>Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities</brief_title>
  <official_title>Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a randomized encouragement trial to encourage use of the existing&#xD;
      mail order pharmacy services among diabetes patients with poor adherence to CVD risk factor&#xD;
      medications in 3 health care systems: Kaiser Permanente Northern California, Harvard Pilgrim,&#xD;
      and Kaiser Permanente Hawaii.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adherence to effective cardiovascular disease (CVD) risk factor medications is associated&#xD;
      with improved CVD risk factor control, fewer hospitalizations, and lower mortality in&#xD;
      patients with diabetes. However, many patients are poorly adherent to medications, and there&#xD;
      are persistent racial/ethnic and socioeconomic disparities in medication adherence.&#xD;
      Traditional clinical trials of interventions to improve medication adherence are often&#xD;
      resource-intensive, and focus exclusively on patient-level barriers to behavior change.&#xD;
      Unsurprisingly, these trials have not led to sustainable, cost-effective approaches to&#xD;
      improve adherence. Health system-level medication adherence interventions that can be&#xD;
      implemented, &quot;scaled up,&quot; and sustained across a wide range of health care delivery settings&#xD;
      are urgently needed. The investigators propose a randomized encouragement trial to encourage&#xD;
      use of existing mail order pharmacy services among diabetes patients with poor adherence to&#xD;
      CVD risk factor medications and who only use retail pharmacies in 3 health care systems:&#xD;
      Kaiser Permanente Northern California, Harvard Pilgrim, and Kaiser Permanente Hawaii. These&#xD;
      combined systems include approximately 300,000 patients with diabetes with diverse&#xD;
      racial/ethnic and socioeconomic backgrounds. Patients with no history of mail order pharmacy&#xD;
      use will be randomized into 2 arms. In addition to examining the impact of the intervention&#xD;
      on medication adherence and CVD risk factor control, the investigators will examine factors&#xD;
      affecting the sustainability and dissemination of the intervention, assess the intervention's&#xD;
      impact on utilization and health care costs, and determine whether the intervention's impact&#xD;
      differs across racial/ethnic and socioeconomic subgroups. This research will provide a&#xD;
      foundation for developing sustainable, system-level approaches to addressing medication&#xD;
      adherence in diabetes patients that can be widely disseminated and implemented across a&#xD;
      diverse array of health care systems.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Using Mail Order Pharmacy after Intervention</measure>
    <time_frame>12 months following the date of outreach into the intervention</time_frame>
    <description>users of the mail order pharmacy service - if they utilized the mail order system to deliver medications anytime in the 12 months following the date of outreach into the intervention</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63026</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Standardized intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standardized intervention</intervention_name>
    <description>Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service</description>
    <arm_group_label>Standardized intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Usual care</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diabetes patients who are users of CVD risk factor medications (antihypertensive&#xD;
             therapies, antihyperlipidemics therapies, and oral antihyperglycemic therapies),&#xD;
&#xD;
          -  Diabetes patients considered to be poorly adherent to CVD risk factor medications&#xD;
             within the prior 12 months&#xD;
&#xD;
          -  Diabetes patients who have not used the mail order pharmacy to fill any prescribed&#xD;
             medications at least once in the prior 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie A Schmittdiel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Scientist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Research</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

